Antimicrobials

This paper reviews clinical and pharmacological characteristics of doxycycline which is currently indicated for the treatment of some common sexually transmitted infections, pelvic inflammatory diseases, lower respiratory tract infections, several …

Antimicrobial resistance is a global challenge for human society. Scientists around the world are trying not to return to the time when antimicrobials were not yet discovered, and millions of people were dying from infections. This article describes …

Polymyxins are often the only agents that remain in vitro active against extensively resistant bacterial pathogens. However, the use of polymyxins is compromised by the number of unresolved issues, including the technical aspects of antimicrobial …

Cephalosporins are one of the most commonly used antimicrobials for the treatment of variety of bacterial infections. Prudent use of the third-generation cephalosporins is important for the control of spread of cephalosporin-resistant Gram-negative …

This paper presents mechanism of action and antimicrobial spectrum of macrolides as well as the known acquired resistance mechanisms in the common pathogens causing community-acquired pneumonia, such as Streptococcus pneumoniae and Mycoplasma …

The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some …

Over the last 20 years, there is an ever-increasing interest in the use of probiotics for the variety of health problems worldwide. However, the evidence base for various probiotic microorganisms differs significantly. This review provides data on …

Over the last decades, probiotic strains for topical administration (including oral cavity) have appeared in clinical practice. Streptococcus salivarius K12 is a promising probiotic for prevention and treatment of the upper respiratory tract and ENT …

Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper …

Objective. To evaluate the efficacy and safety of a step-down strategy from intravenous to oral nemonoxacin versus a step-down strategy from intravenous to oral levofloxacin in the treatment of patients with community-acquired pneumonia. Materials and Methods. This was a phase III randomized, controlled, double-blind, double-dummy, parallel groups (2 groups), multicenter trial to evaluate the efficacy and safety of intravenous and oral nemonoxacin at a daily dose of 500 mg versus levofloxacin (Tavanic®) at a daily dose of 500 mg in the treatment of adult patients with community-acquired pneumonia.